NasdaqGS - Nasdaq Real Time Price USD

Ascendis Pharma A/S (ASND)

174.40
-1.29
(-0.73%)
At close: June 3 at 4:00:01 PM EDT
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
368,701
363,641
266,718
51,174
7,778
Cost of Revenue
54,206
44,258
44,395
12,137
3,523
Gross Profit
314,495
319,383
222,323
39,037
4,255
Operating Expense
648,325
598,146
677,864
600,851
456,047
Operating Income
-333,830
-278,763
-455,541
-561,814
-451,792
Net Non Operating Interest Income Expense
17,759
-39,895
-12,554
-23,256
-3,219
Other Income Expense
-22,208
-54,583
-6,049
7,253
71,067
Pretax Income
-338,279
-373,241
-474,144
-577,817
-383,944
Tax Provision
3,396
4,843
7,303
5,377
-367
Net Income Common Stockholders
-341,675
-378,084
-481,447
-583,194
-383,577
Diluted NI Available to Com Stockholders
-341,675
-378,084
-481,447
-583,194
-383,577
Basic EPS
-5.81
-6.53
-8.55
-10.40
-7.00
Diluted EPS
-5.81
-6.53
-8.55
-10.40
-7.00
Basic Average Shares
58,675.39
57,891.57
56,287.06
56,071.79
54,771.76
Diluted Average Shares
58,675.39
57,891.57
56,287.06
56,071.79
54,771.76
Total Operating Income as Reported
-333,830
-278,763
-455,541
-561,814
-451,792
Total Expenses
702,531
642,404
722,259
612,988
459,570
Net Income from Continuing & Discontinued Operation
-341,675
-378,084
-481,447
-583,194
-383,577
Normalized Income
-320,961.20
-351,156.06
-491,076.88
-602,655
-442,543.97
Interest Income
39,640
14,361
16,857
7,426
692
Interest Expense
33,129
65,504
44,065
30,682
3,911
Net Interest Income
17,759
-39,895
-12,554
-23,256
-3,219
EBIT
-305,150
-307,737
-430,079
-547,135
-380,033
EBITDA
-305,150
-290,023
-411,168
-529,177
-364,642
Reconciled Cost of Revenue
54,206
33,141
31,107
12,137
3,523
Reconciled Depreciation
--
17,714
18,911
17,958
15,391
Net Income from Continuing Operation Net Minority Interest
-341,675
-378,084
-481,447
-583,194
-383,577
Total Unusual Items Excluding Goodwill
-34,523
-34,523
12,346
24,950
59,026
Total Unusual Items
-34,523
-34,523
12,346
24,950
59,026
Normalized EBITDA
-270,627
-255,500
-423,514
-554,127
-423,668
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-13,809.20
-7,595.06
2,716.12
5,489
59.03
12/31/2021 - 1/28/2015

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

GMAB Genmab A/S
21.35
-1.93%
 
BBIO BridgeBio Pharma, Inc.
37.52
+5.81%
 
AKRO Akero Therapeutics, Inc.
51.61
+1.73%
 
RARE Ultragenyx Pharmaceutical Inc.
36.40
+0.72%
 
PCVX Vaxcyte, Inc.
34.65
-1.06%
 
PTGX Protagonist Therapeutics, Inc.
51.06
+1.81%
 
INSM Insmed Incorporated
73.08
+1.95%
 
ALNY Alnylam Pharmaceuticals, Inc.
303.77
-0.76%
 
ARGX argenx SE
576.61
-1.37%
 
RVMD Revolution Medicines, Inc.
40.58
-0.17%